History of PH: Progress in Clinical Management Webinar
Join this interactive discussion on the history of pulmonary hypertension (PH). This is the second presentation of a two-part series, and will focus on the progress in clinical management of PH. The webinar will consist of an interview with a panel of experts considered to be among the founders of the modern PH field.
PH Treatments: What's on the Horizon
With the recent FDA approval of three new treatments in just a few months, the past year has brought exciting advances in PH research! Join Dr. Michael McGoon of the Mayo Clinic for a presentation on the current treatments available for PH, as well as new treatments in the pipeline.
06.20.2014 - 06.22.2014
2014 PHA's International PH Conference and Scientific Sessions
JW Marriott Indianapolis
Indianapolis, Ind., U.S.A.
1st Annual Rio Grande Pulmonary Symposium
Radisson Hotel El Paso Airport
El Paso, Texas
03.27.2014 - 03.29.2014
7th International Conference Neonatal and Childhood Pulmonary Vascular Disease
San Francisco, CA
Over the past decade, great strides have been made in our understanding of the pathobiology of pulmonary vascular disease, and from these findings new therapeutic options have emerged. It is increasingly clear that pulmonary vascular pathology is integral to a number of childhood disorders. In this symposium, we will bring together international experts to explore our current understanding of the basic pathobiology as well as new and future therapies for neonatal, pediatric, and adult pulmonary vascular diseases.
The Lung in Scleroderma
The Westin Kierland Resort
The general objective will be to raise awareness about early diagnosis of SSc-pulmonary hypertension and SSc- interstitial lung disease to discuss ways to effectively treat and manage the conditions. This will involve recent/appropriate/updated knowledge dissemination to clinicians and patients. This activity has been designed to meet the educational needs of physicians, registered nurses, and other health care professionals involved in the management of patients with scleroderma.
04.09.2014 - 04.12.2014
ISHLT 34th Annual Meeting and Scientific Sessions
San Diego, CA, USA
Learn More »
The Alfred P. Fishman Symposium: New Treatment Approaches to Pulmonary Hypertension
Sonesta Hotel Philadelphia
Philadelphia, PA 19103
05.16.2014 - 05.21.2014
ATS Annual Conference
San Diego, CA
The American Thoracic Society’s International Conference features the latest scientific and medical advances in pulmonary, critical care, and sleep medicine. With more than 400 sessions, 800 speakers and, 5,700 research abstracts and case studies, the conference is recognized as the leader in the field.
Learn More »
07.14.2014 - 07.15.2014
1st Annual Drug Discovery and Development for Pulmonary Hypertension Symposium
Doubletree Hotel Bethesda
Bethesda, MD 20814
The Drug Discovery and Development for Pulmonary Hypertension Symposium will be held annually
each summer to bring leading scientists in the fields of pulmonary vascular disease, right heart failure,
and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help
identify the most promising treatments for future development. For this initial meeting we have
assembled a faculty of exceptional achievements and expertise, and have chosen topics in areas that will
influence the development of therapies immediately. Each topic will be critically reviewed by an expert
panel, and open dialogue will allow your voice to be heard.
Alfred P. Fishman Symposium: New Treatment Approaches to Pulmonary Hypertension
Sonesta Hotel Philadelphia 1800 Market Street Philadelphia, PA 19103
A CME-Certified Event: Saturday, April 26, 2014. In conjunction with: Hospital of the University of Pennsylvania Department of Nursing Education, Innovation and Professional Development.
While lung transplantation was the first therapeutic option available for patients with pulmonary hypertension (and continues to be the ultimate treatment for patients who do not respond to other interventions), the last twenty years have seen a surge in research and development of novel medical therapies.
There are 11 FDA-approved medical therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic disease. While these treatments have traditionally been classified by the pathophysiologic pathways they target, their clinical effects are complex in terms of patient response, side effects, and dose titration. In addition, new disease pathways have been targeted in recent preclinical and early phase studies, suggesting that more therapies are on the horizon.
06.02.2014 - 06.03.2014
International CTEPH Conference 2014 Paris
Institut des Cordeliers, Paris, France
The International CTEPH Association (ICA) will held in June 2014 an international Conference fully dedicated to Chronic Thromboembolic Pulmonary Hypertension (CTEPH).